Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cord blood-derived natural killer cells (Shandong Qilu Stem Cells Engineering)
- Development stage
- Preclinical
- Lead developer
- Shandong Qilu Stem Cell Engineering
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is a preclinical-stage cell therapy being developed by Shandong Qilu Stem Cells Engineering (SINOCORD), a Chinese biotechnology company based in Jinan. The therapy involves the adoptive transfer of cryopreserved natural killer (NK) cells isolated and expanded from umbilical cord blood. These cells are designed to mediate direct cytotoxicity against tumor cells, leveraging the innate ability of NK cells to recognize and destroy abnormal cells without prior sensitization. While Shandong Qilu Stem Cells Engineering primarily operates as a cord blood banking service, this research program represents an effort to develop therapeutic applications for stored cord blood units in the treatment of unspecified cancers.
- Other names
- cord blood-derived NK cellsNK cell immunotherapycryopreserved cord blood-derived natural killer cells
02
Targets
FASN (Fatty acid synthase)
Beyond the preview
Go deeper on cord blood-derived natural killer cells (Shandong Qilu Stem Cells Engineering).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cord blood-derived natural killer cells (Shandong Qilu Stem Cells Engineering).